Denison Mines announces $250 million convertible notes offering
OXFORD, UK - Oxford Biomedica PLC (LSE:OXB), a leader in cell and gene therapy manufacturing, disclosed today that Pippa Radcliffe, spouse of Dr. Kyriacos Mitrophanous, the company’s Chief Innovation Officer, exercised options for 1,209 shares at no cost and subsequently sold the same number of shares at a price of £2.9785 each.
The transaction took place on the London Stock Exchange (LON:LSEG) and resulted in an aggregated total of £3,601.01. This event was reported as an initial notification in compliance with the EU Market Abuse Regulation.
Oxford Biomedica is known for its work as a Contract Development and Manufacturing Organization (CDMO), specializing in the creation of gene and cell therapies. The company’s announcement of the share dealings provides transparency in line with market regulations but does not reflect changes in the company’s operations or prospects.
This news comes as part of a routine disclosure by companies listed on the London Stock Exchange, ensuring that financial transactions by insiders are made public to maintain fair trading practices. The information is based on a press release statement from Oxford Biomedica.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.